Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Short-Term Debt issuances (2021 - 2024)

Harvard Bioscience (HBIO) has disclosed Short-Term Debt issuances for 4 consecutive years, with $3.2 million as the latest value for Q3 2024.

  • On a quarterly basis, Short-Term Debt issuances rose 225.0% to $3.2 million in Q3 2024 year-over-year; TTM through Jun 2025 was $3.2 million, a 56.95% decrease, with the full-year FY2024 number at $8.8 million, up 95.56% from a year prior.
  • Short-Term Debt issuances was $3.2 million for Q3 2024 at Harvard Bioscience, up from $3.0 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $3.8 million in Q2 2022 to a low of $1.0 million in Q2 2023.
  • A 4-year average of $2.1 million and a median of $2.1 million in 2021 define the central range for Short-Term Debt issuances.
  • Peak YoY movement for Short-Term Debt issuances: crashed 73.68% in 2023, then soared 225.0% in 2024.
  • Harvard Bioscience's Short-Term Debt issuances stood at $1.8 million in 2021, then skyrocketed by 42.86% to $2.5 million in 2022, then tumbled by 60.0% to $1.0 million in 2023, then skyrocketed by 225.0% to $3.2 million in 2024.
  • Per Business Quant, the three most recent readings for HBIO's Short-Term Debt issuances are $3.2 million (Q3 2024), $3.0 million (Q2 2024), and $2.5 million (Q1 2024).